title: A review and expert opinion of the use of certolizumab for Crohn's disease.
abstract: BACKGROUND
  Crohn's disease (CD) is a chronic, idiopathic, inflammatory bowel disease with no known cure. In those patients with moderate to severe disease, the result is often a clinically debilitating condition. In the last decade, one of the most significant developments in therapy has been a class of biological agents that neutralize TNFa. Certolizumab pegol (CZP) is the most recently FDA approved anti-TNF agent for the induction and maintenance of moderate to severely active Crohn's disease.
  
  
  METHODS
  The currently available evidence regarding the use of CZP in CD, the expected efficacy and possible adverse events associated with this population.
  
  
  CONCLUSIONS
  CZP is a TNFa inhibitor that is a safe and effective agent for treatment of CD. It has several unique features which make it useful in patients with moderate to severe disease.
authors.affiliation: University of Washington, Medical Center, Gastroenterology, 1959 NE Pacific St, WA 98195, USA.
authors.forename: Ashley T
authors.initials: AT
authors.lastname: Evans
authors.forename: Scott D
authors.initials: SD
authors.lastname: Lee
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol